Role of CX3CR1-expressing Cells in Hematologic Malignancy

• Conditions: Diffuse Large B Cell Lymphoma; Multiple Myeloma; CX3CR1 Protein

• Registration Number: NCT02885623
• Lead Sponsor: Saint Vincent's Hospital, Korea

Brief Summary

This study evaluates the clinical significance of CX3CR1-expressing myeloid and lymphoid cells in patients of hematologic malignancy.

Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis and lymphopoiesis. Myeloid cells expressing CD11b play a critical role in sustaining cancer progression. Also, the fractalkine (CX3CL1; Fkn)/CX3CR1 axis plays an important function in the pathophysiology of various forms of cancers. Fkn is the only known ligand for CX3CR1, and it triggers recruitment of CX3CR1-positive cells through its unique receptor, CX3CR1. Therefore, the investigators focused the prognostic significance of CD11b+ myelo-monocytic cells expressing CX3CR1 and CD3+ lymphoid cells expressing CX3CR1 in the clinical outcomes of newly diagnosed Diffuse Large B-cell Lymphoma (DLBCL) and Multiple myeloma (MM).

Detailed Description

Bone marrow aspirates will be obtained from newly diagnosed MM and DLBCL patients at the time of diagnosis and relapse. Peripheral blood will be obtained at the time of diagnosis, finishing treatment, 3 months after treatment and relapse.

The investigators will analyze the cell fractions of CD11b+ CX3CR1+ cells and CD3+CX3CR1+ cells in blood samples by flowcytometry. The investigators will find out the relationship between the tested cells and clinical outcome in MM and DLBCL.

Study Timeline

• Study Start: 2016-08
• Study First Submitted: 2016-08-23
• Study First Submitted QC: 2016-08-30
• Study First Posted: 2016-08-31
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-10
• Last Update Posted: 2017-10-11
• Primary Completion: 2019-08
• Study Completion: 2021-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Subject newly diagnosed multiple myeloma.
• Subject newly diagnosed diffuse large B cell lymphoma.

Exclusion Criteria

• History of other hematologic malignancy
• History of previous chemotherapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression free survival	3 years

Secondary Outcome Measures

Name	Time	Method
overall survival	3 years
Death	3 years

Trial Locations

Locations (1)

The Catholic University of Korea, St.Vincent's hospital; 🇰🇷 Suwon-si, Gyeonggi-do, Korea, Republic of